We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
Information relating to rare side effects after vaccination.
Get help to classify pharmaceutical products used to treat or prevent diseases or ailments (in humans or animals), including comparators used in clinical trials and placebos.
Check what side effects people have reported when they've taken a medicine.
Urgent safety updates arising from pharmacovigilance data, including reported adverse events, for veterinary medicines authorised in the UK.
Organisational definitions of terms concerned with risk and risk-related matters.
A patient alert card is being introduced for men taking finasteride to help raise awareness of the risk of psychiatric side effects and sexual dysfunction, including the potential for sexual dysfunction to persist after treatment has stopped. Healthcare professionals are...
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
Topical steroid products are safe and highly effective treatments for the management of a wide range of inflammatory skin diseases but have important risks, especially with prolonged use at high potency. In the coming months, as a result of regulatory...
Substances that are classed as persistent organic pollutants (POPs) and when you're allowed to use them.
The MHRA will introduce a patient alert card to increase awareness among men taking finasteride about potential psychiatric and sexual side effects
Information for patients, healthcare professionals and developers of new medicines
From 1 January 2014 herbal smoking products will have Tobacco Products Duty charged on them unless they are to be used exclusively for medical purposes.
Information on how to report a serious undesirable effect (SUE) or safeguarding issue for cosmetic products.
Guidance for prescribing vets on the use of the cascade.
Systematic review of the evidence around the health effects associated with exposure to setae of OPM larvae and a summary of the findings.
Product Safety Report for Fabrique par Rodis B.B.Clear Lightening Dark Spot Remover presenting a serious chemical risk.
This was a observational study, using data collected at all multidrug-resistant-TB treatment centres in Nigeria
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).